Typhoid Vi polysaccharide vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Typhim Vi
Generic Name
Typhoid Vi polysaccharide vaccine
DrugBank Accession Number
DB10803
Background

Typhoid Vi polysaccharide vaccine is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Salmonella typhi TY2 Vi polysaccharide antigen
  • Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
TypherixLiquid25 mcg / 0.5 mLIntramuscularGlaxosmithkline Inc2000-11-272017-12-21Canada flag
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUS flag
Typhim ViSolution25 mcg/1IntramuscularSanofi Pasteur Limited1995-12-31Not applicableCanada flag
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUS flag
Typhim ViInjection, solution25 ug/0.5mLIntramuscularSanofi Pasteur Inc.1994-11-28Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
VivaximTyphoid Vi polysaccharide vaccine (25 mcg) + Hepatitis A Vaccine (160 unit)Solution; SuspensionIntramuscularSanofi Pasteur Limited2005-11-09Not applicableCanada flag
Vivaxim VaccineTyphoid Vi polysaccharide vaccine (25 mcg/0.5ml) + Hepatitis A Vaccine (160 i.u./0.5 ml)SuspensionIntramuscularSANOFI-AVENTIS SINGAPORE PTE. LTD.2009-07-08Not applicable

Categories

ATC Codes
J07AP03 — Typhoid, purified polysaccharide antigen
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7194H8W3KT
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910909
RxNav
807219

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4CompletedPreventionParatyphoid Fever / Salmonella Typhi Infection2
4TerminatedPreventionAging / Inflammation1
4Unknown StatusDiagnosticSpecific Polysaccharide Antibody Deficiency1
4Unknown StatusPreventionHealthy Subjects (HS)1
3CompletedPreventionBacterial Infections / Salmonella Infections / Salmonella Typhi Infection1
3CompletedPreventionEncephalitis, Japanese B / Meningococcal Disease / Meningococcal Meningitis / Rabies / Salmonella Typhi Infection / Yellow Fever1
2Active Not RecruitingPreventionPlasmodium Infections1
2CompletedPreventionDengue Dengue Fever Dengue Hemorrhagic Fever / Dengue Diseases / Dengue Fever / Dengue Virus1
2CompletedPreventionSalmonella Typhi Infection3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntramuscular25 mcg/0.5ml
LiquidIntramuscular25 mcg / 0.5 mL
InjectionIntramuscular0.5 ml
Injection, solutionIntramuscular25 ug/0.5mL
SolutionIntramuscular25 mcg/1
SolutionIntramuscular; Subcutaneous0.025 mg
Injection, solutionIntramuscular; Subcutaneous
InjectionIntramuscular; Subcutaneous25 micrograms
Injection, solutionIntramuscular
InjectionIntramuscular; Subcutaneous0.025 mg
Injection, suspensionIntramuscular0.5 mL
Solution; suspensionIntramuscular
SuspensionIntramuscular160 i.u./0.5 ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:04 / Updated on October 19, 2021 07:39